p21-ras Effector Domain Mutants Constructed by "Cassette" Mutagenesis

Literature Cited

• Adari, H., D. R. Lowy, В. M. Willumsen, C. J. Der, and F. McCormick. 1988. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 240:518-521.
   PubMed Web of Science ®Google Scholar
• Barbacid, M. 1987. ras genes. Annu. Rev. Biochem. 56:779-827.
   PubMed Web of Science ®Google Scholar
• Cales, C., J. F. Hancock, C. J. Marshall, and A. Hall. 1988. The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product. Nature (London) 332:548-551.
   PubMed Web of Science ®Google Scholar
• Field, J., D. Broek, R. Kataoka, and M. Wigier. 1987. Guanine nucleotide activation of, and competition between, RAS proteins from Saccharomyces cerevisiae. Mol. Cell. Biol. 7:2128-2133.
   PubMedGoogle Scholar
• Furth, M. E., L. J. Davis, B. Fleurdelys, and E. M. Scolnick. 1982. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and the cellular ras gene family. J. Virol. 43:294-304.
   PubMed Web of Science ®Google Scholar
• Gibbs, J. B., I. S. Sigal, M. Poe, and E. M. Scolnick. 1984. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl. Acad. Sci. USA 81:5704-5708.
   PubMed Web of Science ®Google Scholar
• Jhappan, C., G. F. Vande Woude, and T. S. Robins. 1986. Transduction of host cellular sequences by a retroviral shuttle vector. J. Virol. 60:750-753.
   PubMedGoogle Scholar
• Lathe, R., M. Kieny, S. Skory, and J. P. Lecocq. 1984. Linker tailing: unphosphorylated linker oligonucleotides for joining DNA termini. DNA 3:173-182.
   PubMedGoogle Scholar
• Lowy, D. R., and B. M. Willumsen. 1986. The ras gene family. Cancer Surv. 5:275-289.
   PubMedGoogle Scholar
• Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
   Google Scholar
• Marshall, M. S., J. B. Gibbs, E. M. Scolnick, and I. S. Sigal. 1988. An adenylate cyclase from Saccharomyces cerevisiae that is stimulated by RAS proteins with effector mutations. Mol. Cell. Biol. 8:52-61.
   PubMedGoogle Scholar
• McGrath, J. P., D. J. Capon, D. V. Goeddel, and A. D. Levinson. 1984. Comparative biochemical properties of normal and activated human ras p21 protein. Nature (London) 310:644-649.
   PubMed Web of Science ®Google Scholar
• Mulcahy, L. S., M. R. Smith, and D. W. Stacey. 1985. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature (London) 313:241-243.
   PubMed Web of Science ®Google Scholar
• Papageorge, A. G., D. R. Lowy, and E. M. Scolnick. 1982. Comparative biochemical properties of p21 ras molecules coded for by viral and cellular ras genes. J. Virol. 44:509-519.
   PubMed Web of Science ®Google Scholar
• Reddy, E. P., R. K. Reynolds, E. Santos, and M. Barbacid. 1982. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (London) 300:149-152.
   PubMed Web of Science ®Google Scholar
• Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
   PubMed Web of Science ®Google Scholar
• Satoh, T., S. Nakamura, and Y. Kaziro. 1987. Induction of neurite formation in PC 12 cells by microinjection of proto-oncogenic Ha-ras protein preincubated with guanosine-5′-O-(3-thiotriphosphate). Mol. Cell. Biol. 7:4553-4556.
   PubMed Web of Science ®Google Scholar
• Shih, T. Y., and M. O. Weeks. 1984. Oncogenes and cancer: p21 ras genes. Cancer Invest. 2:109-123.
   PubMed Web of Science ®Google Scholar
• Sigal, I. S., J. B. Gibbs, J. S. D’Alonzo, and E. M. Scolnick. 1986. Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proc. Natl. Acad. Sci. USA 83:4725-4729.
   PubMed Web of Science ®Google Scholar
• Sweet, R. W., S. Yoroyama, Т. Ramata, J. R. Feramisco, M. Rosenberg, and N. Gross. 1984. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature (London) 311:273-275.
   PubMed Web of Science ®Google Scholar
• Tabin, C. J., S. M. Bradley, C. I. Bargmann, R. A. Weinberg, A. G. Papageorge, E. M. Scolnick, R. Dhar, D. R. Lowy, and E. H. Chang. 1982. Mechanism of action of a human oncogene. Nature (London) 300:143-149.
   PubMed Web of Science ®Google Scholar
• Toda, T., I. Uno, T. Ishikawa, S. Powers, T. Kataoka, D. Broaek, S. Cameron, J. Broach, K. Matsumoto, and M. Wigier. 1985. In yeast RAS proteins are controlling elements of adenylate cyclase. Cell 40:27-36.
   PubMed Web of Science ®Google Scholar
• Trahey, M., and F. McCormick. 1987. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238:542-545.
   PubMed Web of Science ®Google Scholar
• Wells, J. Α., Μ. Vasser, and D. B. Powers. 1985. Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites. Gene 34:315-323.
   PubMed Web of Science ®Google Scholar
• Willumsen, Β. Μ., A. Christensen, Ν. L. Hubbert, A. G. Papageorge, and D. R. Lowy. 1984. The p21 ras C-terminus is required for transformation and membrane association. Nature (London) 310:583-586.
   PubMed Web of Science ®Google Scholar
• Willumsen, B. M., A. G. Papageorge, H.-F. Kung, E. Bekesi, T. Robins, M. Johnsen, W. C. Vass, and D. R. Lowy. 1986. Mutational analysis of a ras catalytic domain. Mol. Cell. Biol. 6:2646-2654.
   PubMed Web of Science ®Google Scholar